| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 60 | 2025 | 606 | 8.780 |
Why?
|
| Surgery, Computer-Assisted | 25 | 2024 | 101 | 7.300 |
Why?
|
| Mouth Neoplasms | 34 | 2024 | 120 | 6.620 |
Why?
|
| Carcinoma, Squamous Cell | 41 | 2024 | 683 | 4.670 |
Why?
|
| Cone-Beam Computed Tomography | 13 | 2024 | 39 | 3.700 |
Why?
|
| Imaging, Three-Dimensional | 20 | 2023 | 580 | 3.300 |
Why?
|
| Mandible | 11 | 2024 | 78 | 3.300 |
Why?
|
| Ontario | 54 | 2025 | 148 | 3.210 |
Why?
|
| Thyroid Neoplasms | 18 | 2025 | 343 | 3.080 |
Why?
|
| Flow Cytometry | 24 | 2024 | 1178 | 2.980 |
Why?
|
| Neoplasms | 27 | 2025 | 2671 | 2.600 |
Why?
|
| Mandibular Reconstruction | 6 | 2024 | 12 | 2.400 |
Why?
|
| Osteotomy | 7 | 2024 | 119 | 2.100 |
Why?
|
| Single-Cell Analysis | 7 | 2025 | 313 | 2.000 |
Why?
|
| Paranasal Sinuses | 4 | 2022 | 80 | 1.900 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2024 | 2691 | 1.690 |
Why?
|
| Humans | 275 | 2025 | 137585 | 1.680 |
Why?
|
| Photochemotherapy | 5 | 2025 | 44 | 1.590 |
Why?
|
| Margins of Excision | 10 | 2024 | 50 | 1.460 |
Why?
|
| Free Tissue Flaps | 7 | 2024 | 52 | 1.450 |
Why?
|
| Nanoparticles | 10 | 2025 | 481 | 1.390 |
Why?
|
| Rabbits | 14 | 2024 | 794 | 1.380 |
Why?
|
| Unsupervised Machine Learning | 2 | 2021 | 22 | 1.380 |
Why?
|
| Carcinoma | 11 | 2023 | 240 | 1.370 |
Why?
|
| Optical Imaging | 3 | 2020 | 64 | 1.340 |
Why?
|
| Neoplasm Staging | 24 | 2024 | 1389 | 1.300 |
Why?
|
| Germinal Center | 3 | 2022 | 58 | 1.280 |
Why?
|
| Signal Transduction | 21 | 2025 | 5079 | 1.280 |
Why?
|
| Lymphatic Metastasis | 13 | 2020 | 352 | 1.250 |
Why?
|
| Maxilla | 3 | 2019 | 38 | 1.250 |
Why?
|
| Mandibular Neoplasms | 4 | 2019 | 25 | 1.240 |
Why?
|
| Middle Aged | 120 | 2025 | 33479 | 1.230 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2019 | 36 | 1.200 |
Why?
|
| Aged | 101 | 2025 | 23961 | 1.180 |
Why?
|
| Pandemics | 17 | 2024 | 1639 | 1.150 |
Why?
|
| Lymphoma, Follicular | 7 | 2017 | 40 | 1.150 |
Why?
|
| Glioblastoma | 2 | 2023 | 345 | 1.150 |
Why?
|
| Oropharyngeal Neoplasms | 11 | 2023 | 63 | 1.140 |
Why?
|
| Osteoradionecrosis | 3 | 2024 | 6 | 1.100 |
Why?
|
| Male | 140 | 2025 | 67762 | 1.060 |
Why?
|
| Endoscopy | 5 | 2024 | 318 | 1.050 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2023 | 630 | 1.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 123 | 1.000 |
Why?
|
| Bone Plates | 4 | 2024 | 77 | 1.000 |
Why?
|
| Thyroidectomy | 11 | 2025 | 106 | 0.990 |
Why?
|
| Melanoma | 4 | 2021 | 760 | 0.980 |
Why?
|
| Female | 142 | 2025 | 73304 | 0.980 |
Why?
|
| Mass Spectrometry | 3 | 2019 | 739 | 0.970 |
Why?
|
| Image Cytometry | 2 | 2022 | 8 | 0.960 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2024 | 1079 | 0.960 |
Why?
|
| Benzofurans | 1 | 2025 | 21 | 0.950 |
Why?
|
| Surgical Oncology | 2 | 2023 | 27 | 0.950 |
Why?
|
| Retrospective Studies | 67 | 2025 | 15657 | 0.950 |
Why?
|
| B-Lymphocytes | 4 | 2022 | 847 | 0.940 |
Why?
|
| Carcinoma, Papillary | 4 | 2021 | 81 | 0.930 |
Why?
|
| Papillomavirus Infections | 10 | 2023 | 325 | 0.930 |
Why?
|
| Adult | 100 | 2025 | 37929 | 0.930 |
Why?
|
| Aged, 80 and over | 51 | 2025 | 7635 | 0.920 |
Why?
|
| Tongue Neoplasms | 4 | 2023 | 27 | 0.910 |
Why?
|
| Orbit | 3 | 2021 | 70 | 0.910 |
Why?
|
| Porphyrins | 6 | 2025 | 23 | 0.910 |
Why?
|
| Biological Products | 2 | 2025 | 216 | 0.900 |
Why?
|
| Thoracic Surgery | 2 | 2024 | 132 | 0.900 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2023 | 73 | 0.900 |
Why?
|
| Temporal Bone | 4 | 2019 | 45 | 0.890 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 2022 | 130 | 0.880 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2019 | 1396 | 0.850 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2021 | 43 | 0.830 |
Why?
|
| Skull Base | 3 | 2015 | 53 | 0.810 |
Why?
|
| Prognosis | 35 | 2024 | 4030 | 0.800 |
Why?
|
| Monocytes | 4 | 2022 | 563 | 0.790 |
Why?
|
| Watchful Waiting | 5 | 2025 | 81 | 0.790 |
Why?
|
| Multimodal Imaging | 2 | 2021 | 113 | 0.770 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 510 | 0.770 |
Why?
|
| Precision Medicine | 4 | 2021 | 429 | 0.760 |
Why?
|
| Cadaver | 12 | 2022 | 296 | 0.760 |
Why?
|
| Indocyanine Green | 3 | 2020 | 24 | 0.750 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 373 | 0.730 |
Why?
|
| Phototherapy | 1 | 2021 | 39 | 0.730 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 364 | 0.730 |
Why?
|
| Proteomics | 5 | 2022 | 1111 | 0.730 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2021 | 66 | 0.730 |
Why?
|
| Biomarkers, Tumor | 17 | 2021 | 1276 | 0.720 |
Why?
|
| Cohort Studies | 27 | 2024 | 5742 | 0.720 |
Why?
|
| Surgeons | 6 | 2024 | 297 | 0.710 |
Why?
|
| Bone Neoplasms | 5 | 2024 | 247 | 0.710 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 4295 | 0.700 |
Why?
|
| Fluorescent Dyes | 2 | 2021 | 321 | 0.700 |
Why?
|
| Neck Dissection | 7 | 2024 | 23 | 0.700 |
Why?
|
| Monitoring, Intraoperative | 3 | 2020 | 56 | 0.700 |
Why?
|
| Picornaviridae Infections | 1 | 2021 | 47 | 0.700 |
Why?
|
| Mandibular Osteotomy | 4 | 2024 | 6 | 0.690 |
Why?
|
| Prospective Studies | 25 | 2025 | 7604 | 0.680 |
Why?
|
| Nasal Surgical Procedures | 1 | 2020 | 6 | 0.680 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2024 | 28 | 0.670 |
Why?
|
| Cell Line, Tumor | 16 | 2025 | 3412 | 0.670 |
Why?
|
| CD40 Antigens | 2 | 2019 | 89 | 0.660 |
Why?
|
| Sentinel Lymph Node | 1 | 2020 | 45 | 0.660 |
Why?
|
| Cells | 1 | 2020 | 25 | 0.650 |
Why?
|
| Emergency Service, Hospital | 8 | 2025 | 2069 | 0.650 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2019 | 40 | 0.650 |
Why?
|
| Masks | 1 | 2020 | 63 | 0.640 |
Why?
|
| Reproducibility of Results | 22 | 2021 | 3284 | 0.640 |
Why?
|
| Computer Simulation | 6 | 2024 | 978 | 0.640 |
Why?
|
| Machine Learning | 3 | 2024 | 493 | 0.640 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 14 | 0.640 |
Why?
|
| Parathyroid Neoplasms | 1 | 2019 | 13 | 0.630 |
Why?
|
| Education | 1 | 2020 | 108 | 0.630 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 224 | 0.630 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 674 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 86 | 0.610 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 321 | 0.610 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 286 | 0.610 |
Why?
|
| CD40 Ligand | 1 | 2019 | 41 | 0.610 |
Why?
|
| Monitoring, Immunologic | 1 | 2018 | 25 | 0.600 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 332 | 0.600 |
Why?
|
| Contrast Media | 3 | 2020 | 467 | 0.590 |
Why?
|
| Nestin | 1 | 2018 | 19 | 0.590 |
Why?
|
| Quality Improvement | 5 | 2024 | 1178 | 0.580 |
Why?
|
| Waiting Lists | 4 | 2025 | 266 | 0.580 |
Why?
|
| Sarcoma | 4 | 2023 | 188 | 0.570 |
Why?
|
| Software | 7 | 2023 | 665 | 0.570 |
Why?
|
| Phagocytes | 1 | 2019 | 101 | 0.570 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 134 | 0.560 |
Why?
|
| Otolaryngology | 2 | 2019 | 96 | 0.560 |
Why?
|
| Bone Transplantation | 4 | 2024 | 90 | 0.560 |
Why?
|
| Airway Obstruction | 1 | 2019 | 162 | 0.560 |
Why?
|
| Head | 2 | 2016 | 105 | 0.560 |
Why?
|
| Photosensitizing Agents | 3 | 2025 | 41 | 0.560 |
Why?
|
| Referral and Consultation | 4 | 2025 | 786 | 0.550 |
Why?
|
| Immunologic Memory | 2 | 2021 | 353 | 0.550 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 303 | 0.550 |
Why?
|
| Organ Transplantation | 1 | 2020 | 250 | 0.540 |
Why?
|
| Animals | 34 | 2025 | 36940 | 0.530 |
Why?
|
| Phosphorylation | 10 | 2022 | 1759 | 0.530 |
Why?
|
| Survival Rate | 18 | 2024 | 1972 | 0.530 |
Why?
|
| Patient-Specific Modeling | 2 | 2024 | 41 | 0.530 |
Why?
|
| Down-Regulation | 1 | 2019 | 657 | 0.520 |
Why?
|
| Occupational Exposure | 1 | 2020 | 341 | 0.510 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2015 | 41 | 0.510 |
Why?
|
| Laryngeal Neoplasms | 5 | 2020 | 39 | 0.510 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 2253 | 0.500 |
Why?
|
| Length of Stay | 7 | 2024 | 1215 | 0.500 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2022 | 142 | 0.500 |
Why?
|
| Algorithms | 9 | 2021 | 1704 | 0.500 |
Why?
|
| Printing, Three-Dimensional | 4 | 2024 | 95 | 0.500 |
Why?
|
| Sensitivity and Specificity | 8 | 2022 | 1946 | 0.500 |
Why?
|
| Phantoms, Imaging | 5 | 2021 | 152 | 0.490 |
Why?
|
| Disease-Free Survival | 15 | 2022 | 686 | 0.490 |
Why?
|
| Neck | 2 | 2015 | 101 | 0.490 |
Why?
|
| Macrophages | 2 | 2023 | 1547 | 0.490 |
Why?
|
| Deglutition Disorders | 3 | 2024 | 143 | 0.480 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 210 | 0.470 |
Why?
|
| Dendritic Cells | 1 | 2019 | 483 | 0.470 |
Why?
|
| Specialties, Surgical | 1 | 2016 | 75 | 0.470 |
Why?
|
| Breast | 1 | 2016 | 151 | 0.460 |
Why?
|
| Papillomaviridae | 5 | 2017 | 125 | 0.460 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 530 | 0.450 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 145 | 0.450 |
Why?
|
| Tooth | 1 | 2014 | 42 | 0.430 |
Why?
|
| Models, Theoretical | 1 | 2018 | 578 | 0.430 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 136 | 0.430 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 1238 | 0.430 |
Why?
|
| Lymphocytes | 3 | 2023 | 397 | 0.430 |
Why?
|
| Follow-Up Studies | 18 | 2025 | 5131 | 0.420 |
Why?
|
| Fossils | 1 | 2014 | 75 | 0.420 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2013 | 17 | 0.420 |
Why?
|
| Radiotherapy Dosage | 3 | 2024 | 268 | 0.420 |
Why?
|
| Models, Anatomic | 7 | 2019 | 93 | 0.410 |
Why?
|
| Neoplasm Transplantation | 4 | 2021 | 257 | 0.400 |
Why?
|
| Estrogens | 1 | 2016 | 367 | 0.400 |
Why?
|
| Elective Surgical Procedures | 3 | 2024 | 179 | 0.390 |
Why?
|
| Young Adult | 25 | 2024 | 13209 | 0.390 |
Why?
|
| Esophagectomy | 2 | 2024 | 131 | 0.390 |
Why?
|
| Surgical Procedures, Operative | 4 | 2024 | 259 | 0.390 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 127 | 0.390 |
Why?
|
| Postoperative Complications | 5 | 2023 | 2654 | 0.380 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 712 | 0.380 |
Why?
|
| Adenocarcinoma | 6 | 2023 | 940 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3566 | 0.380 |
Why?
|
| Hospital-Physician Relations | 1 | 2012 | 4 | 0.380 |
Why?
|
| Regional Medical Programs | 1 | 2012 | 7 | 0.380 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 916 | 0.380 |
Why?
|
| Radiopharmaceuticals | 2 | 2025 | 178 | 0.370 |
Why?
|
| Thoracic Neoplasms | 2 | 2024 | 37 | 0.370 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 38 | 0.360 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2004 | 21 | 0.360 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 1996 | 0.360 |
Why?
|
| Lateral Ventricles | 2 | 2023 | 35 | 0.350 |
Why?
|
| Surgical Flaps | 4 | 2020 | 130 | 0.350 |
Why?
|
| Skull Neoplasms | 2 | 2024 | 23 | 0.340 |
Why?
|
| Combined Modality Therapy | 9 | 2024 | 1236 | 0.340 |
Why?
|
| Lipids | 2 | 2025 | 672 | 0.340 |
Why?
|
| Internet | 3 | 2015 | 655 | 0.340 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2022 | 19 | 0.340 |
Why?
|
| X-Ray Microtomography | 2 | 2020 | 94 | 0.340 |
Why?
|
| Databases as Topic | 1 | 2010 | 67 | 0.340 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 2129 | 0.330 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 2526 | 0.330 |
Why?
|
| Lymphocyte Subsets | 1 | 2010 | 87 | 0.330 |
Why?
|
| Equipment Design | 5 | 2020 | 522 | 0.330 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 900 | 0.330 |
Why?
|
| Physician's Role | 1 | 2012 | 211 | 0.330 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2022 | 389 | 0.320 |
Why?
|
| Hospitalization | 6 | 2025 | 2199 | 0.320 |
Why?
|
| Ilium | 2 | 2020 | 25 | 0.320 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 34 | 0.320 |
Why?
|
| Chemoradiotherapy | 4 | 2020 | 225 | 0.310 |
Why?
|
| Phosphoproteins | 3 | 2016 | 338 | 0.310 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 5472 | 0.310 |
Why?
|
| Models, Statistical | 4 | 2024 | 669 | 0.310 |
Why?
|
| Survival Analysis | 12 | 2022 | 1325 | 0.310 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2006 | 48 | 0.310 |
Why?
|
| Immunophenotyping | 4 | 2024 | 318 | 0.310 |
Why?
|
| Oximes | 2 | 2018 | 24 | 0.300 |
Why?
|
| Herpesvirus 4, Human | 4 | 2004 | 166 | 0.300 |
Why?
|
| Publishing | 1 | 2010 | 147 | 0.290 |
Why?
|
| Delayed Diagnosis | 3 | 2024 | 91 | 0.290 |
Why?
|
| Lymph Nodes | 4 | 2020 | 491 | 0.290 |
Why?
|
| Operating Rooms | 2 | 2020 | 123 | 0.290 |
Why?
|
| Fluorescence | 5 | 2020 | 160 | 0.290 |
Why?
|
| DNA, Neoplasm | 4 | 2016 | 164 | 0.290 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2008 | 5 | 0.290 |
Why?
|
| Leukemia | 3 | 2021 | 240 | 0.280 |
Why?
|
| Pyrimidinones | 2 | 2018 | 113 | 0.280 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 224 | 0.280 |
Why?
|
| Canada | 8 | 2024 | 418 | 0.280 |
Why?
|
| Incidence | 5 | 2022 | 2804 | 0.280 |
Why?
|
| STAT1 Transcription Factor | 3 | 2022 | 72 | 0.280 |
Why?
|
| Mice | 13 | 2024 | 17787 | 0.270 |
Why?
|
| Maxillary Neoplasms | 2 | 2018 | 9 | 0.270 |
Why?
|
| Imidazoles | 2 | 2018 | 238 | 0.270 |
Why?
|
| Mutation | 8 | 2024 | 3958 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 2 | 2006 | 320 | 0.270 |
Why?
|
| Treatment Outcome | 23 | 2024 | 10811 | 0.270 |
Why?
|
| Pyridones | 2 | 2018 | 168 | 0.260 |
Why?
|
| Cell Communication | 2 | 2024 | 315 | 0.260 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 322 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2006 | 327 | 0.260 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 56 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 404 | 0.260 |
Why?
|
| Surgical Wound Infection | 3 | 2019 | 307 | 0.260 |
Why?
|
| Frailty | 2 | 2019 | 170 | 0.250 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 986 | 0.250 |
Why?
|
| Decision Making | 4 | 2024 | 900 | 0.250 |
Why?
|
| Otologic Surgical Procedures | 1 | 2006 | 14 | 0.250 |
Why?
|
| Cells, Cultured | 8 | 2021 | 4193 | 0.250 |
Why?
|
| Phenotype | 5 | 2022 | 3196 | 0.250 |
Why?
|
| National Health Programs | 2 | 2023 | 23 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 558 | 0.250 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2006 | 75 | 0.250 |
Why?
|
| Heterografts | 3 | 2022 | 138 | 0.250 |
Why?
|
| Tyrosine | 1 | 2006 | 222 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2023 | 752 | 0.240 |
Why?
|
| Copper Radioisotopes | 1 | 2025 | 2 | 0.240 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2023 | 385 | 0.240 |
Why?
|
| DNA, Viral | 4 | 2014 | 364 | 0.240 |
Why?
|
| Endometrial Neoplasms | 2 | 2019 | 201 | 0.240 |
Why?
|
| Theranostic Nanomedicine | 2 | 2015 | 15 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 233 | 0.240 |
Why?
|
| Photosensitivity Disorders | 1 | 2025 | 9 | 0.240 |
Why?
|
| Speech-Language Pathology | 1 | 2025 | 24 | 0.240 |
Why?
|
| Comprehensive Health Care | 1 | 2025 | 24 | 0.240 |
Why?
|
| Laryngectomy | 3 | 2020 | 19 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 106 | 0.230 |
Why?
|
| Scapula | 2 | 2018 | 46 | 0.230 |
Why?
|
| Adolescent | 19 | 2024 | 21513 | 0.230 |
Why?
|
| Oral Surgical Procedures | 2 | 2016 | 8 | 0.230 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 1043 | 0.230 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2022 | 267 | 0.230 |
Why?
|
| Xerostomia | 1 | 2024 | 17 | 0.230 |
Why?
|
| Carcinogenesis | 2 | 2019 | 217 | 0.230 |
Why?
|
| Mandibular Diseases | 1 | 2024 | 12 | 0.230 |
Why?
|
| Neutrophils | 2 | 2022 | 1238 | 0.230 |
Why?
|
| Facial Neoplasms | 1 | 2024 | 19 | 0.230 |
Why?
|
| Cochlea | 2 | 2019 | 72 | 0.230 |
Why?
|
| Metabolomics | 2 | 2022 | 678 | 0.230 |
Why?
|
| Tumor Burden | 3 | 2021 | 309 | 0.220 |
Why?
|
| Pilot Projects | 4 | 2024 | 1710 | 0.220 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2024 | 141 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 622 | 0.220 |
Why?
|
| Fibula | 2 | 2023 | 43 | 0.220 |
Why?
|
| Skin | 3 | 2025 | 752 | 0.220 |
Why?
|
| Quality of Life | 6 | 2024 | 2892 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2024 | 220 | 0.220 |
Why?
|
| Nasopharynx | 1 | 2004 | 76 | 0.220 |
Why?
|
| Structure-Activity Relationship | 1 | 2025 | 570 | 0.220 |
Why?
|
| Epithelial Cell Adhesion Molecule | 2 | 2021 | 13 | 0.220 |
Why?
|
| Molecular Structure | 1 | 2025 | 489 | 0.220 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2021 | 66 | 0.210 |
Why?
|
| Cochlear Implants | 2 | 2019 | 91 | 0.210 |
Why?
|
| Radiation Oncology | 1 | 2024 | 82 | 0.210 |
Why?
|
| Biofeedback, Psychology | 1 | 2024 | 37 | 0.210 |
Why?
|
| Registries | 5 | 2023 | 2035 | 0.210 |
Why?
|
| Time-to-Treatment | 2 | 2024 | 205 | 0.210 |
Why?
|
| Gene Expression | 3 | 2009 | 1502 | 0.210 |
Why?
|
| Mouth Diseases | 1 | 2024 | 45 | 0.210 |
Why?
|
| Liposomes | 3 | 2020 | 223 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 1091 | 0.210 |
Why?
|
| Disease Progression | 11 | 2024 | 2757 | 0.210 |
Why?
|
| Allografts | 1 | 2024 | 146 | 0.210 |
Why?
|
| Serpins | 2 | 2015 | 31 | 0.210 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 191 | 0.210 |
Why?
|
| Heterozygote | 1 | 2024 | 293 | 0.210 |
Why?
|
| Gene Editing | 1 | 2024 | 80 | 0.210 |
Why?
|
| Gene Expression Profiling | 10 | 2017 | 1774 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1692 | 0.200 |
Why?
|
| Feasibility Studies | 3 | 2022 | 956 | 0.200 |
Why?
|
| Cataract Extraction | 1 | 2024 | 98 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2006 | 528 | 0.200 |
Why?
|
| Patient Care Team | 2 | 2025 | 631 | 0.200 |
Why?
|
| Pneumonectomy | 1 | 2024 | 152 | 0.200 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 125 | 0.200 |
Why?
|
| Time Factors | 7 | 2025 | 6828 | 0.200 |
Why?
|
| Saliva | 1 | 2024 | 242 | 0.200 |
Why?
|
| Osteosarcoma | 1 | 2023 | 74 | 0.200 |
Why?
|
| Dental Caries | 1 | 2024 | 155 | 0.200 |
Why?
|
| Computer-Aided Design | 2 | 2019 | 43 | 0.190 |
Why?
|
| Thyroid Gland | 2 | 2021 | 94 | 0.190 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2025 | 177 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2015 | 69 | 0.190 |
Why?
|
| Social Class | 1 | 2024 | 282 | 0.190 |
Why?
|
| HMGB1 Protein | 1 | 2022 | 50 | 0.190 |
Why?
|
| Leukoplakia, Oral | 2 | 2014 | 11 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 115 | 0.190 |
Why?
|
| Eustachian Tube | 1 | 2022 | 8 | 0.190 |
Why?
|
| Cytokines | 4 | 2022 | 2085 | 0.190 |
Why?
|
| CD57 Antigens | 1 | 2021 | 17 | 0.190 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2022 | 17 | 0.190 |
Why?
|
| Ear Diseases | 1 | 2022 | 15 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 135 | 0.190 |
Why?
|
| Proportional Hazards Models | 7 | 2025 | 1266 | 0.190 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 893 | 0.190 |
Why?
|
| Immunomagnetic Separation | 1 | 2021 | 5 | 0.190 |
Why?
|
| Cottontail rabbit papillomavirus | 1 | 2021 | 4 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 126 | 0.190 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 14 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 955 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 1313 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 146 | 0.180 |
Why?
|
| Myositis | 1 | 2022 | 52 | 0.180 |
Why?
|
| Immunity | 1 | 2022 | 143 | 0.180 |
Why?
|
| Salvage Therapy | 3 | 2018 | 142 | 0.180 |
Why?
|
| Zygoma | 1 | 2021 | 8 | 0.180 |
Why?
|
| CD4 Antigens | 1 | 2021 | 141 | 0.180 |
Why?
|
| Computational Biology | 3 | 2015 | 644 | 0.180 |
Why?
|
| Health Services Misuse | 1 | 2021 | 33 | 0.180 |
Why?
|
| Microscopy | 1 | 2023 | 152 | 0.180 |
Why?
|
| Anilides | 1 | 2021 | 73 | 0.180 |
Why?
|
| Glutaminase | 1 | 2021 | 11 | 0.180 |
Why?
|
| Rhinovirus | 1 | 2021 | 58 | 0.180 |
Why?
|
| Open Reading Frames | 1 | 2021 | 123 | 0.180 |
Why?
|
| Nose Neoplasms | 2 | 2016 | 25 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2019 | 1118 | 0.170 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 157 | 0.170 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2021 | 50 | 0.170 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 13 | 0.170 |
Why?
|
| Palatine Tonsil | 2 | 2018 | 48 | 0.170 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 26 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 402 | 0.170 |
Why?
|
| Mouth | 2 | 2019 | 87 | 0.170 |
Why?
|
| Equipment Safety | 1 | 2020 | 37 | 0.170 |
Why?
|
| CD28 Antigens | 1 | 2020 | 53 | 0.170 |
Why?
|
| Fas Ligand Protein | 1 | 2020 | 60 | 0.170 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 434 | 0.170 |
Why?
|
| Nephritis | 1 | 2020 | 23 | 0.170 |
Why?
|
| Thyroid Nodule | 1 | 2021 | 56 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 43 | 0.170 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 228 | 0.170 |
Why?
|
| Anemia, Aplastic | 1 | 2020 | 38 | 0.170 |
Why?
|
| Surveys and Questionnaires | 7 | 2025 | 5778 | 0.170 |
Why?
|
| Prolyl Hydroxylases | 1 | 2020 | 4 | 0.170 |
Why?
|
| Thrombospondins | 1 | 2020 | 9 | 0.170 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2020 | 22 | 0.170 |
Why?
|
| Biopsy | 5 | 2016 | 1129 | 0.170 |
Why?
|
| Cell Line | 4 | 2021 | 2847 | 0.160 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 252 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2021 | 159 | 0.160 |
Why?
|
| Injections | 1 | 2020 | 183 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2021 | 83 | 0.160 |
Why?
|
| Supraglottitis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Collagen Type IV | 1 | 2020 | 28 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 192 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2025 | 363 | 0.160 |
Why?
|
| Pyridines | 2 | 2021 | 506 | 0.160 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 115 | 0.160 |
Why?
|
| Automation | 1 | 2020 | 95 | 0.160 |
Why?
|
| Croup | 1 | 2019 | 19 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 10 | 0.160 |
Why?
|
| Iodine Radioisotopes | 2 | 2017 | 145 | 0.160 |
Why?
|
| Vocal Cord Paralysis | 1 | 2019 | 28 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 217 | 0.160 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 211 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 654 | 0.160 |
Why?
|
| Laryngeal Diseases | 1 | 2019 | 31 | 0.160 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 116 | 0.160 |
Why?
|
| Workload | 2 | 2024 | 167 | 0.160 |
Why?
|
| Peritoneum | 1 | 2019 | 44 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 82 | 0.160 |
Why?
|
| Delivery of Health Care | 4 | 2024 | 951 | 0.160 |
Why?
|
| Immunohistochemistry | 9 | 2023 | 1738 | 0.160 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 118 | 0.160 |
Why?
|
| RNA, Viral | 2 | 2022 | 656 | 0.160 |
Why?
|
| Documentation | 1 | 2021 | 194 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2021 | 759 | 0.150 |
Why?
|
| Up-Regulation | 3 | 2016 | 843 | 0.150 |
Why?
|
| Age Factors | 8 | 2025 | 3295 | 0.150 |
Why?
|
| Adenoids | 1 | 2018 | 12 | 0.150 |
Why?
|
| Parotid Gland | 2 | 2015 | 23 | 0.150 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 855 | 0.150 |
Why?
|
| STAT5 Transcription Factor | 3 | 2021 | 57 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2020 | 455 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 167 | 0.150 |
Why?
|
| Artifacts | 1 | 2019 | 129 | 0.150 |
Why?
|
| Emotions | 1 | 2024 | 548 | 0.150 |
Why?
|
| Psychometrics | 3 | 2021 | 720 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2021 | 368 | 0.150 |
Why?
|
| Forecasting | 1 | 2020 | 389 | 0.150 |
Why?
|
| Organizational Objectives | 1 | 2018 | 73 | 0.150 |
Why?
|
| Antibodies, Neoplasm | 1 | 2018 | 34 | 0.150 |
Why?
|
| Tuberous Sclerosis | 1 | 2019 | 55 | 0.150 |
Why?
|
| Thoracoscopy | 2 | 2018 | 56 | 0.150 |
Why?
|
| Laryngostenosis | 1 | 2019 | 51 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2019 | 131 | 0.150 |
Why?
|
| Income | 2 | 2023 | 202 | 0.150 |
Why?
|
| Orthopedic Procedures | 1 | 2021 | 216 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 73 | 0.150 |
Why?
|
| Cochlear Implantation | 1 | 2019 | 76 | 0.150 |
Why?
|
| Respiratory System | 1 | 2019 | 157 | 0.150 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 125 | 0.150 |
Why?
|
| Physicians | 2 | 2025 | 910 | 0.140 |
Why?
|
| Physical Examination | 1 | 2019 | 241 | 0.140 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2018 | 12 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2019 | 128 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 625 | 0.140 |
Why?
|
| Polymers | 1 | 2022 | 490 | 0.140 |
Why?
|
| Appointments and Schedules | 1 | 2018 | 89 | 0.140 |
Why?
|
| Cisplatin | 1 | 2020 | 320 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 1171 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 217 | 0.140 |
Why?
|
| Reference Values | 1 | 2019 | 816 | 0.140 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2017 | 5 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 301 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.140 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 257 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 362 | 0.130 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 156 | 0.130 |
Why?
|
| Surgical Instruments | 1 | 2017 | 51 | 0.130 |
Why?
|
| Proteins | 2 | 2019 | 1009 | 0.130 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 1142 | 0.130 |
Why?
|
| Immunoglobulin M | 3 | 2022 | 289 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 21 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 1007 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 216 | 0.130 |
Why?
|
| SMARCB1 Protein | 1 | 2016 | 31 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 156 | 0.130 |
Why?
|
| Palate, Hard | 2 | 2015 | 6 | 0.130 |
Why?
|
| Hearing Loss | 1 | 2019 | 221 | 0.130 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 29 | 0.130 |
Why?
|
| Myoepithelioma | 1 | 2015 | 4 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 889 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 59 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 412 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 73 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 410 | 0.120 |
Why?
|
| Palatal Neoplasms | 1 | 2015 | 7 | 0.120 |
Why?
|
| Photoacoustic Techniques | 1 | 2015 | 6 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 44 | 0.120 |
Why?
|
| Parotid Neoplasms | 1 | 2015 | 16 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2022 | 622 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 890 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 976 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 403 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 530 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 194 | 0.120 |
Why?
|
| Ablation Techniques | 1 | 2015 | 36 | 0.120 |
Why?
|
| Apoptosis | 3 | 2020 | 2553 | 0.120 |
Why?
|
| Cluster Analysis | 5 | 2020 | 499 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 94 | 0.120 |
Why?
|
| Uterus | 1 | 2016 | 215 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 938 | 0.120 |
Why?
|
| Sepsis | 1 | 2022 | 617 | 0.120 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 16 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2031 | 0.120 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 1289 | 0.120 |
Why?
|
| Logistic Models | 5 | 2024 | 2074 | 0.120 |
Why?
|
| Risk Factors | 9 | 2020 | 10388 | 0.120 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 16 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2019 | 691 | 0.110 |
Why?
|
| Cortactin | 1 | 2014 | 8 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2020 | 697 | 0.110 |
Why?
|
| Chromatin | 2 | 2016 | 519 | 0.110 |
Why?
|
| Chordoma | 1 | 2014 | 14 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2014 | 35 | 0.110 |
Why?
|
| Telemedicine | 1 | 2024 | 862 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 183 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2020 | 827 | 0.110 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2014 | 23 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2013 | 692 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 156 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2020 | 342 | 0.110 |
Why?
|
| Political Systems | 1 | 2014 | 1 | 0.110 |
Why?
|
| Egypt, Ancient | 1 | 2014 | 2 | 0.110 |
Why?
|
| Sudan | 1 | 2014 | 5 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 80 | 0.110 |
Why?
|
| Health Services | 1 | 2015 | 107 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2015 | 171 | 0.110 |
Why?
|
| Paleodontology | 1 | 2014 | 13 | 0.110 |
Why?
|
| Gene Fusion | 1 | 2014 | 27 | 0.110 |
Why?
|
| Genome | 1 | 2016 | 300 | 0.110 |
Why?
|
| History, Ancient | 1 | 2014 | 54 | 0.110 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 72 | 0.110 |
Why?
|
| Human papillomavirus 16 | 2 | 2013 | 35 | 0.110 |
Why?
|
| Depression | 2 | 2023 | 1397 | 0.110 |
Why?
|
| Transcription Factor AP-1 | 1 | 2014 | 92 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2018 | 820 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 49 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2475 | 0.110 |
Why?
|
| Social Stigma | 1 | 2016 | 137 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 181 | 0.110 |
Why?
|
| Papilloma | 1 | 2014 | 52 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 2 | 2015 | 399 | 0.110 |
Why?
|
| Information Dissemination | 2 | 2020 | 218 | 0.110 |
Why?
|
| Comorbidity | 4 | 2020 | 1622 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 90 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2005 | 767 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 564 | 0.100 |
Why?
|
| Sex Factors | 4 | 2023 | 2071 | 0.100 |
Why?
|
| Gene Flow | 1 | 2014 | 86 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2014 | 223 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 136 | 0.100 |
Why?
|
| Tonsillar Neoplasms | 1 | 2013 | 11 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 718 | 0.100 |
Why?
|
| Caregivers | 1 | 2021 | 877 | 0.100 |
Why?
|
| Health Services Research | 1 | 2016 | 404 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 29 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 804 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2014 | 261 | 0.100 |
Why?
|
| Risk Assessment | 5 | 2023 | 3457 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2014 | 290 | 0.100 |
Why?
|
| Pelvic Bones | 1 | 2015 | 129 | 0.100 |
Why?
|
| Genes, ras | 1 | 1993 | 97 | 0.100 |
Why?
|
| Syk Kinase | 2 | 2016 | 21 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 319 | 0.100 |
Why?
|
| Clonal Evolution | 1 | 2013 | 45 | 0.100 |
Why?
|
| Pediatrics | 1 | 2020 | 1101 | 0.090 |
Why?
|
| Survivors | 1 | 2016 | 493 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2025 | 786 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 1910 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2016 | 152 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 617 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2007 | 614 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2011 | 11 | 0.090 |
Why?
|
| Nucleic Acid Probes | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2016 | 185 | 0.090 |
Why?
|
| Molecular Probe Techniques | 1 | 2011 | 10 | 0.090 |
Why?
|
| Histone Deacetylase 1 | 1 | 2011 | 25 | 0.090 |
Why?
|
| Genome, Human | 3 | 2024 | 425 | 0.090 |
Why?
|
| Body Image | 2 | 2024 | 95 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2019 | 1069 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2022 | 3556 | 0.090 |
Why?
|
| Research Design | 2 | 2018 | 1139 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 648 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2013 | 289 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 249 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2016 | 234 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2025 | 332 | 0.080 |
Why?
|
| CD79 Antigens | 2 | 2022 | 15 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 67 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 57 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2014 | 404 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 801 | 0.080 |
Why?
|
| DNA Damage | 2 | 2018 | 420 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2010 | 101 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 100 | 0.080 |
Why?
|
| Microsurgery | 1 | 2010 | 75 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 119 | 0.080 |
Why?
|
| Face | 2 | 2021 | 173 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 6 | 2015 | 1062 | 0.080 |
Why?
|
| China | 3 | 2020 | 217 | 0.080 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2009 | 26 | 0.080 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2009 | 2 | 0.080 |
Why?
|
| Smoking | 3 | 2015 | 1627 | 0.080 |
Why?
|
| Biomarkers | 4 | 2022 | 4149 | 0.080 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2009 | 4 | 0.080 |
Why?
|
| Receptor, trkA | 1 | 2009 | 18 | 0.080 |
Why?
|
| Ossification, Heterotopic | 1 | 2009 | 16 | 0.080 |
Why?
|
| Lung | 2 | 2021 | 4060 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 118 | 0.080 |
Why?
|
| Kinetics | 2 | 2017 | 1670 | 0.080 |
Why?
|
| Receptor, trkB | 1 | 2009 | 33 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 135 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 416 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2016 | 434 | 0.080 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2008 | 4 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 1502 | 0.080 |
Why?
|
| Glycolysis | 2 | 2021 | 321 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 27 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2010 | 810 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 143 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 184 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2024 | 730 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2025 | 1386 | 0.070 |
Why?
|
| Intraoperative Period | 1 | 2008 | 59 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2010 | 325 | 0.070 |
Why?
|
| Disease | 1 | 2009 | 98 | 0.070 |
Why?
|
| Cell Death | 2 | 2022 | 374 | 0.070 |
Why?
|
| Lymphoma | 1 | 2009 | 208 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2021 | 382 | 0.070 |
Why?
|
| Hospitals | 2 | 2024 | 691 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 2167 | 0.070 |
Why?
|
| Leadership | 1 | 2012 | 388 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2016 | 1100 | 0.070 |
Why?
|
| Asthma | 1 | 2021 | 2295 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 451 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2020 | 367 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 236 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2023 | 210 | 0.070 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 171 | 0.070 |
Why?
|
| Esthetics | 2 | 2010 | 51 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 828 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2009 | 405 | 0.070 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 114 | 0.060 |
Why?
|
| Patient Participation | 2 | 2020 | 420 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 539 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 1430 | 0.060 |
Why?
|
| Peptide Mapping | 1 | 2006 | 64 | 0.060 |
Why?
|
| Rats | 2 | 2025 | 5647 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 658 | 0.060 |
Why?
|
| United States | 3 | 2018 | 14841 | 0.060 |
Why?
|
| In Situ Hybridization | 3 | 2014 | 316 | 0.060 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2005 | 9 | 0.060 |
Why?
|
| Quinazolines | 1 | 2007 | 251 | 0.060 |
Why?
|
| Bite Force | 1 | 2024 | 2 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 1483 | 0.060 |
Why?
|
| Mastication | 1 | 2024 | 13 | 0.060 |
Why?
|
| Isotope Labeling | 1 | 2025 | 81 | 0.060 |
Why?
|
| Rats, Inbred F344 | 1 | 2025 | 265 | 0.060 |
Why?
|
| Radiation Oncologists | 1 | 2024 | 5 | 0.060 |
Why?
|
| Lovastatin | 1 | 2005 | 37 | 0.060 |
Why?
|
| Hospitals, Proprietary | 1 | 2024 | 4 | 0.060 |
Why?
|
| Hemostatics | 1 | 2005 | 52 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 328 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2004 | 33 | 0.060 |
Why?
|
| Carcinogens, Environmental | 1 | 2004 | 14 | 0.060 |
Why?
|
| Hospitals, Public | 1 | 2024 | 29 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2005 | 150 | 0.060 |
Why?
|
| Financing, Government | 1 | 2024 | 47 | 0.060 |
Why?
|
| Electrodiagnosis | 1 | 2024 | 17 | 0.050 |
Why?
|
| Bone Substitutes | 1 | 2024 | 28 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 1092 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 56 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2024 | 62 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1509 | 0.050 |
Why?
|
| Dental Care | 1 | 2024 | 26 | 0.050 |
Why?
|
| Dogs | 1 | 2025 | 413 | 0.050 |
Why?
|
| Child | 8 | 2022 | 21935 | 0.050 |
Why?
|
| Patient Selection | 2 | 2022 | 696 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2023 | 1357 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 2844 | 0.050 |
Why?
|
| Models, Biological | 2 | 2009 | 1783 | 0.050 |
Why?
|
| Speech Intelligibility | 1 | 2023 | 5 | 0.050 |
Why?
|
| Glossectomy | 1 | 2023 | 4 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 390 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 110 | 0.050 |
Why?
|
| ras Proteins | 1 | 2004 | 153 | 0.050 |
Why?
|
| Fiducial Markers | 1 | 2023 | 9 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2024 | 96 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 455 | 0.050 |
Why?
|
| Bone Conduction | 1 | 2023 | 23 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2024 | 98 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2024 | 312 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2833 | 0.050 |
Why?
|
| Reference Standards | 1 | 2023 | 186 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2024 | 523 | 0.050 |
Why?
|
| Tongue | 1 | 2023 | 81 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 363 | 0.050 |
Why?
|
| Deglutition | 1 | 2023 | 72 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 198 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2023 | 136 | 0.050 |
Why?
|
| Prevalence | 3 | 2018 | 2734 | 0.050 |
Why?
|
| Stress, Mechanical | 1 | 2024 | 485 | 0.050 |
Why?
|
| Calreticulin | 1 | 2022 | 28 | 0.050 |
Why?
|
| Viral Load | 1 | 2004 | 466 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 36 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 283 | 0.050 |
Why?
|
| Bone Regeneration | 1 | 2022 | 26 | 0.050 |
Why?
|
| Light | 1 | 2025 | 381 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 53 | 0.050 |
Why?
|
| Cell Count | 1 | 2022 | 324 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2023 | 128 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 398 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2022 | 75 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 257 | 0.050 |
Why?
|
| Polyesters | 1 | 2022 | 76 | 0.050 |
Why?
|
| Janus Kinase 1 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2015 | 356 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 67 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 128 | 0.040 |
Why?
|
| Nose | 1 | 2001 | 67 | 0.040 |
Why?
|
| Alternaria | 1 | 2021 | 13 | 0.040 |
Why?
|
| Calgranulin B | 1 | 2021 | 10 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2021 | 129 | 0.040 |
Why?
|
| Pyroglyphidae | 1 | 2021 | 19 | 0.040 |
Why?
|
| Nova Scotia | 1 | 2020 | 8 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2021 | 68 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 68 | 0.040 |
Why?
|
| Larynx, Artificial | 1 | 2020 | 2 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 92 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2023 | 547 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 168 | 0.040 |
Why?
|
| Surgical Wound | 1 | 2020 | 23 | 0.040 |
Why?
|
| Tretinoin | 1 | 2021 | 123 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 2 | 2014 | 364 | 0.040 |
Why?
|
| Glutamine | 1 | 2021 | 103 | 0.040 |
Why?
|
| Listeriosis | 1 | 2021 | 70 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2021 | 107 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 445 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 171 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 61 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 199 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2020 | 39 | 0.040 |
Why?
|
| Fear | 1 | 2023 | 338 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2010 | 1316 | 0.040 |
Why?
|
| Observer Variation | 2 | 2017 | 343 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 204 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 193 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2004 | 442 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 108 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 491 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 126 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 176 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 20 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 872 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 201 | 0.040 |
Why?
|
| Self Concept | 1 | 2001 | 253 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2023 | 620 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2000 | 144 | 0.040 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 148 | 0.040 |
Why?
|
| Linear Models | 1 | 2022 | 849 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2022 | 317 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 5757 | 0.040 |
Why?
|
| Iohexol | 1 | 2019 | 23 | 0.040 |
Why?
|
| Ethmoid Sinus | 1 | 1998 | 10 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2019 | 52 | 0.040 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1998 | 8 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2020 | 153 | 0.040 |
Why?
|
| Ki-67 Antigen | 2 | 2014 | 112 | 0.040 |
Why?
|
| Software Validation | 1 | 2018 | 10 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2019 | 67 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 283 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 552 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 273 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 601 | 0.040 |
Why?
|
| Thoracic Wall | 1 | 2018 | 18 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 425 | 0.040 |
Why?
|
| Bioprinting | 1 | 2019 | 30 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2018 | 20 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 376 | 0.040 |
Why?
|
| Streptomyces | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Extracts | 1 | 2018 | 21 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 652 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2017 | 20 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 363 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 128 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 778 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2019 | 157 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 117 | 0.040 |
Why?
|
| Laryngoscopy | 1 | 2019 | 109 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2022 | 423 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 98 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 256 | 0.030 |
Why?
|
| Propensity Score | 1 | 2019 | 294 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 275 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 143 | 0.030 |
Why?
|
| Recurrence | 2 | 2013 | 1060 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 179 | 0.030 |
Why?
|
| Telomerase | 1 | 2000 | 250 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 200 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 384 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 261 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 347 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 29 | 0.030 |
Why?
|
| Histones | 1 | 2022 | 636 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 911 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2016 | 77 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 314 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2014 | 1070 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 271 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2020 | 396 | 0.030 |
Why?
|
| General Surgery | 1 | 2018 | 173 | 0.030 |
Why?
|
| Rural Population | 1 | 2020 | 563 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2018 | 286 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 392 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 375 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 641 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 92 | 0.030 |
Why?
|
| Palliative Care | 1 | 2023 | 758 | 0.030 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2015 | 11 | 0.030 |
Why?
|
| Dimyristoylphosphatidylcholine | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cholesterol Esters | 1 | 2015 | 8 | 0.030 |
Why?
|
| Mesocricetus | 1 | 2015 | 39 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 433 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 2668 | 0.030 |
Why?
|
| Salivary Ducts | 1 | 2015 | 3 | 0.030 |
Why?
|
| Pyrans | 1 | 2015 | 5 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 283 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 86 | 0.030 |
Why?
|
| Suspensions | 1 | 2015 | 36 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2019 | 482 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2015 | 32 | 0.030 |
Why?
|
| Submandibular Gland | 1 | 2015 | 20 | 0.030 |
Why?
|
| Cell Tracking | 1 | 2015 | 17 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 683 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 417 | 0.030 |
Why?
|
| Stem Cells | 1 | 2019 | 594 | 0.030 |
Why?
|
| Cell Self Renewal | 1 | 2015 | 56 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2015 | 30 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 102 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2015 | 51 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1020 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2015 | 31 | 0.030 |
Why?
|
| Thoracoscopes | 1 | 2014 | 3 | 0.030 |
Why?
|
| Bronchoscopes | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2001 | 812 | 0.030 |
Why?
|
| Weight Loss | 1 | 2020 | 787 | 0.030 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2014 | 6 | 0.030 |
Why?
|
| Accessory Nerve | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Plasticity | 1 | 2015 | 35 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 2014 | 25 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1050 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2019 | 425 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 34 | 0.030 |
Why?
|
| Radiology | 1 | 2017 | 180 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2014 | 87 | 0.030 |
Why?
|
| Mental Health | 1 | 2021 | 726 | 0.030 |
Why?
|
| Benzamides | 1 | 2015 | 216 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 274 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 350 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 437 | 0.030 |
Why?
|
| Salivary Glands | 1 | 2014 | 33 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 469 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 447 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 30 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 1496 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 374 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2014 | 71 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 692 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 118 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2015 | 466 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 948 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 2828 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 76 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1991 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 698 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 971 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2015 | 189 | 0.030 |
Why?
|
| Radiography, Panoramic | 1 | 2013 | 12 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 294 | 0.030 |
Why?
|
| Mastectomy | 1 | 2014 | 137 | 0.030 |
Why?
|
| Dentition | 1 | 2013 | 17 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 367 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 209 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 7 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 411 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 317 | 0.030 |
Why?
|
| E-Selectin | 1 | 2013 | 57 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2013 | 30 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 57 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 182 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 363 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2013 | 87 | 0.020 |
Why?
|
| DNA Replication | 1 | 2014 | 238 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 6079 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 89 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1993 | 104 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 591 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 265 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 42 | 0.020 |
Why?
|
| Mammaplasty | 1 | 2014 | 105 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 169 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2018 | 1793 | 0.020 |
Why?
|
| Swine | 1 | 2014 | 775 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2013 | 216 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1993 | 150 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 318 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 231 | 0.020 |
Why?
|
| Diamines | 1 | 2011 | 4 | 0.020 |
Why?
|
| Exons | 1 | 1993 | 355 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 117 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 521 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 601 | 0.020 |
Why?
|
| Data Mining | 1 | 2012 | 116 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2011 | 33 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 32 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1477 | 0.020 |
Why?
|
| Color | 1 | 2011 | 76 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 250 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2011 | 89 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2607 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 302 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 2186 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 26 | 0.020 |
Why?
|
| Forehead | 1 | 2010 | 6 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 307 | 0.020 |
Why?
|
| Scalp | 1 | 2010 | 35 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 195 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2011 | 125 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2010 | 85 | 0.020 |
Why?
|
| Quinolines | 1 | 2011 | 178 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2011 | 124 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1570 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1993 | 660 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 304 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 431 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 822 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2009 | 90 | 0.020 |
Why?
|
| DNA Primers | 2 | 2001 | 515 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 24 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 565 | 0.020 |
Why?
|
| SEER Program | 1 | 2010 | 227 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 554 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 32 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2014 | 828 | 0.020 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2008 | 19 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 152 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 1120 | 0.020 |
Why?
|
| Wound Healing | 1 | 2010 | 331 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 535 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 73 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2007 | 72 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 75 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1272 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2010 | 624 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 171 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 1719 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 449 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2005 | 47 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2005 | 57 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 2005 | 80 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 2057 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 27 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 11074 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2005 | 255 | 0.010 |
Why?
|
| Multigene Family | 1 | 2004 | 198 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 57 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 530 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 399 | 0.010 |
Why?
|
| Norway | 1 | 2002 | 43 | 0.010 |
Why?
|
| Anesthesia | 1 | 2005 | 189 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1164 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 18 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 357 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2002 | 36 | 0.010 |
Why?
|
| Papilloma, Inverted | 1 | 2001 | 3 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2001 | 26 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2001 | 12 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2001 | 15 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 219 | 0.010 |
Why?
|
| Methylation | 1 | 2001 | 230 | 0.010 |
Why?
|
| Polynesia | 1 | 2000 | 4 | 0.010 |
Why?
|
| New Zealand | 1 | 2000 | 56 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 2000 | 49 | 0.010 |
Why?
|
| Laryngeal Mucosa | 1 | 2000 | 8 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1993 | 0.010 |
Why?
|
| Densitometry | 1 | 2000 | 36 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2000 | 55 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 1113 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2000 | 99 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2000 | 147 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1998 | 27 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2001 | 430 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2000 | 342 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2001 | 771 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1250 | 0.010 |
Why?
|
| Risk | 1 | 1999 | 912 | 0.010 |
Why?
|
| Cause of Death | 1 | 1998 | 434 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 655 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2000 | 996 | 0.010 |
Why?
|